We've upgraded AI Search on TaxTMI with two powerful modes:
1. Basic • Quick overview summary answering your query with references• Category-wise results to explore all relevant documents on TaxTMI
2. Advanced • Includes everything in Basic • Detailed report covering: - Overview Summary - Governing Provisions [Acts, Notifications, Circulars] - Relevant Case Laws - Tariff / Classification / HSN - Expert views from TaxTMI - Practical Guidance with immediate steps and dispute strategy
• Also highlights how each document is relevant to your query, helping you quickly understand key insights without reading the full text.Help Us Improve - by giving the rating with each AI Result:
Tribunal Overturns Decision, Upholds Modvat Credit for Exported Goods, Reinforces Government's Pro-Export Policy. The Tribunal set aside the impugned order, allowing the appeal and providing consequential relief. It found that the judgment in Norris Medicines Ltd. v. ...
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
The Tribunal set aside the impugned order, allowing the appeal and providing consequential relief. It found that the judgment in Norris Medicines Ltd. v. CCE & C, Surat supported the appellant's claim, emphasizing that Modvat credit cannot be denied for goods exported under bond. The Tribunal highlighted the government's policy to encourage exports and ensure that exported products and inputs used in export products are not burdened with domestic levies.
Issues involved: Appeal against disallowance of Modvat credit u/r 57-I of Central Excise Rules, 1944 for pharmaceutical products classified under Chapter 30 of Central Excise Tariff Act, 1985.
1. The appellant contested the disallowance of Modvat credit by the lower authority under Rule 57-I, claiming that even if the final product is exempted, credit availed cannot be denied if duty was paid on the final product. They argued that the product was classified as a P or P Medicine and that the Modvat credit should not be denied for exported goods. The appellant also highlighted that Rule 57-I should apply only in cases of error, omission, or misconstruction by the manufacturer, which was not the situation in this case.
2. The Commissioner (Appeals) upheld the lower authority's decision, leading the appellants to challenge the order.
3. The appellant cited the judgment in Norris Medicines Ltd. v. CCE & CC Surat, along with other relevant cases, to support their claim that the Modvat credit cannot be denied for exported goods. They argued that the impugned order should be set aside based on the settled legal position.
4. The Departmental Representative reiterated the department's stance.
Judgment: After considering the submissions and reviewing the cited case-law, the Tribunal found that the judgment in Norris Medicines Ltd. v. CCE & C, Surat supported the appellant's claim. The Tribunal noted that the Bombay Bench had allowed the assessee's claim, emphasizing that once goods are exported under bond, Modvat credit cannot be denied. The Tribunal highlighted the government's policy to encourage exports and ensure that exported products and inputs used in export products are not burdened with domestic levies. Consequently, the Tribunal set aside the impugned order and allowed the appeal, providing consequential relief as per law.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.